Cost analysis for patients with presumed pulmonary tuberculosis attended in the public health system of Rio de Janeiro, Brazil.
Nenhuma Miniatura disponível
Data
2022
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Background: In last years, few attention has given to the patient’s prediagnostic costs when evaluating the introduction of new technologies
for tuberculosis (TB) and in this context, this study evaluated patient’s costs and cost‑effectiveness incurred with TB diagnosis comparing
BactecTMMGITTM960 system (MGIT) to the Löwestein–Jensen (LJ) culture in a health center and in a university hospital, in Rio de Janeiro City,
Brazil. Methods: Patient’s mean costs were evaluated during the diagnosis process and cost‑effectiveness based on mean time in days for the
adoption of appropriate clinical anti‑TB treatment in two health units comparing culture by means LJ and MGIT. Results: The mean cost of LJ
and MGIT in the health center was U. S. dollars (US$) 26.6 and US$ 45.13, respectively, and in university hospital was US$ 206.87 and US$
285.48, respectively. Comparing the two approaches for TB diagnosis incurred by the patients, the incremental cost‑effectiveness of MGIT
compared to LJ was US$ 0.88 and US$ 4.03 per patient, respectively, to reduce the average time to adopt appropriate treatment. Conclusions:
The culture method directly impacts patient costs while waiting for the correct diagnosis and contributing to aggravating costs with patients
with TB.
Descrição
Palavras-chave
Clinical study, Diagnosis, Mean cost
Citação
VATER, M. C. et al. Cost analysis for patients with presumed pulmonary tuberculosis attended in the public health system of Rio de Janeiro, Brazil. International Journal of Mycobateriology, v. 10, p. 136-141, 2021. Disponível em: <https://www.ijmyco.org/article.asp?issn=2212-5531;year=2021;volume=10;issue=2;spage=136;epage=141;aulast=Vater>. Acesso em: 11 out. 2022.